Nykode Therapeutics
Nykode Therapeutics, formerly known as Nykode, is a pioneering biotechnology company headquartered in Norway. Founded in 2007, Nykode has established itself as a leader in the development of innovative therapeutic solutions, particularly in the fields of immunotherapy and personalised medicine. The company focuses on harnessing the power of its proprietary Vaxart platform to create unique therapeutic vaccines aimed at treating various cancers and infectious diseases. With a strong presence in Europe and North America, Nykode Therapeutics has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing healthcare. The company’s core offerings, characterised by their ability to stimulate robust immune responses, set them apart in a competitive market. Nykode's dedication to innovation and patient-centric solutions positions it as a notable player in the biotechnology industry.
DitchCarbon Score
How does Nykode Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nykode Therapeutics's score of 16 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nykode Therapeutics's reported carbon emissions
In 2023, Nykode Therapeutics reported total carbon emissions of approximately 5,355,000 kg CO2e. This figure includes 460 kg CO2e from Scope 1 emissions, 141,400 kg CO2e from Scope 2 emissions (market-based), and a significant 5,349,000 kg CO2e from Scope 3 emissions. In the previous year, 2022, the company had total emissions of about 557,400 kg CO2e, with Scope 1 emissions at 30 kg CO2e, Scope 2 emissions (market-based) at 204,700 kg CO2e, and Scope 3 emissions at 540,100 kg CO2e. Despite the substantial emissions reported, Nykode Therapeutics has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests a need for further commitment to climate action within the industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 30 | 000 |
| Scope 2 | 204,700 | 000,000 |
| Scope 3 | 540,100 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nykode Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
